甲胎蛋白阳性胃癌的分子机制与诊疗现状  

Mechanisms, clinical diagnosis and treatment of alphafetoprotein-producing gastric cancer: The research status

作　　者：陆泳言 姜文凯(综述) 李硕 易剑锋(审校)[1,3] LU Yongyan;JIANG Wenkai;LI Shuo;YI Jianfeng(First Clinical Medical College of Lanzhou University,Lanzhou 730000;Second Clinical Medical College of Lanzhou University,Lanzhou 730000;First Clinical Medical School,Gansu University of Chinese Medicine,Lanzhou 730000,China)

机构地区：[1]兰州大学第一临床医学院,兰州730000 [2]兰州大学第二临床医学院,兰州730000 [3]甘肃中医药大学第一临床医学院,兰州730000

出　　处：《临床与病理杂志》2022年第9期2255-2261,共7页Journal of Clinical and Pathological Research

基　　金：甘肃中医药大学科学研究与创新基金(2020KCZD-6);甘肃省高等学校创新基金(2021B-161)。

摘　　要：甲胎蛋白阳性胃癌(alpha-fetoprotein-producing gastric cancer,AFPGC)是一种特殊类型胃癌,与普通胃癌相比具有独特的分子机制和临床病理特征,因其转移率高、预后差、易误诊等特点近年来引起临床医师关注。近年来,血管内皮生长因子(vascular endothelial growth factor,VEGF)、人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)、细胞间质上皮转换因子(cellular-mesenchymal epithelial transition factor,c-Met)、婆罗双树样基因4(spalt-like transcription factor4,SALL4)和微RNA(micro RNA,miRNA)等分子在AFPGC中的过表达一定程度上揭示了相关信号通路和致癌分子与此类胃癌的关系,化学治疗药物和阿帕替尼、曲妥珠单抗等分子靶向药物也显示出了对AFPGC的疗效。Alpha-fetoprotein-producing gastric cancer(AFPGC) is a special type of gastric cancer with unique molecular mechanism and clinicopathological features compared with conventional gastric cancer. It has already attracted the attention of clinicians in recent years due to its high metastasis rate, poor prognosis and frequent misdiagnosis. In recent years, the overexpression of molecules such as vascular endothelial growth factor(VEGF), human epidermal growth factor receptor 2(HER2), cellular-mesenchymal epithelial transition factor(c-Met), spalt-like transcription factor 4(SALL4) and microRNA(miRNA) in AFPGC could reveal the correlation between relevant signaling pathways and carcinogenic molecule and this kind of gastric cancer in some way. Molecular targeting drugs such as chemotherapeutic drugs, apatinib and trastuzumab have also shown efficacy against AFPGC.

关 键 词：甲胎蛋白阳性胃癌 分子机制 靶向治疗 

分 类 号：R735.2[医药卫生—肿瘤]